Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TGTX 
TG Therapeutics Inc (TGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/07/2026: TGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.57
1 Year Target Price $44.57
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.95% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/07/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.82B USD | Price to earnings Ratio 10.95 | 1Y Target Price 44.57 |
Price to earnings Ratio 10.95 | 1Y Target Price 44.57 | ||
Volume (30-day avg) 7 | Beta 1.86 | 52 Weeks Range 25.28 - 46.48 | Updated Date 01/8/2026 |
52 Weeks Range 25.28 - 46.48 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 84.13% | Operating Margin (TTM) 18.16% |
Management Effectiveness
Return on Assets (TTM) 7.98% | Return on Equity (TTM) 111.96% |
Valuation
Trailing PE 10.95 | Forward PE 23.15 | Enterprise Value 4938895743 | Price to Sales(TTM) 9.06 |
Enterprise Value 4938895743 | Price to Sales(TTM) 9.06 | ||
Enterprise Value to Revenue 9.29 | Enterprise Value to EBITDA 42.86 | Shares Outstanding 158759451 | Shares Floating 140386483 |
Shares Outstanding 158759451 | Shares Floating 140386483 | ||
Percent Insiders 6.78 | Percent Institutions 64.38 |
Upturn AI SWOT
TG Therapeutics Inc
Company Overview
History and Background
TG Therapeutics Inc. was founded in 2011 and is a biopharmaceutical company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases. Key milestones include significant clinical trial progress for its lead drug candidates, Ublituximab and Umbralisib, and subsequent regulatory submissions.
Core Business Areas
- Oncology: Development of novel therapies for blood cancers like Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL), and other B-cell malignancies.
- Immunology: Research and development of treatments for autoimmune diseases, leveraging its expertise in B-cell modulation.
Leadership and Structure
TG Therapeutics Inc. is led by Michael S. Weiss (Executive Chairman and CEO) and has a management team with extensive experience in drug development, clinical trials, and commercialization. The company operates with a lean structure focused on advancing its pipeline.
Top Products and Market Share
Key Offerings
- Ublituximab: A novel, chimeric antibody designed to target the CD20 B-cell antigen. It is being developed as a monotherapy and in combination with other agents for various B-cell malignancies and autoimmune diseases. Competitors include rituximab (Genentech/Roche) and ocrelizumab (Genentech/Roche).
- Umbralisib: A dual inhibitor of PI3K-delta and CK1-epsilon, aimed at treating certain B-cell malignancies. It has received accelerated approval for specific indications. Competitors include various PI3K inhibitors and BTK inhibitors like Ibrutinib (AbbVie/Janssen).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology and immunology, is characterized by high R&D costs, lengthy regulatory approval processes, and significant competition. There is a growing demand for innovative treatments for hematologic malignancies and autoimmune disorders.
Positioning
TG Therapeutics Inc. is positioned as a developer of innovative, targeted therapies with a focus on B-cell biology. Its dual-pronged approach in oncology and immunology provides diversification. Its competitive advantage lies in its novel drug candidates and a streamlined development strategy.
Total Addressable Market (TAM)
The TAM for B-cell malignancies and autoimmune diseases is substantial, estimated in the tens of billions of dollars globally. TG Therapeutics Inc. aims to capture a significant portion of this market with its lead candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for significant therapeutic impact.
- Experienced management team with a track record in drug development.
- Focus on B-cell biology offers synergistic opportunities in oncology and immunology.
- Active clinical development programs with ongoing data readouts.
Weaknesses
- Reliance on a few key drug candidates, increasing pipeline risk.
- Navigating complex regulatory pathways and potential delays.
- Significant capital requirements for late-stage clinical trials and commercialization.
- Limited historical commercialization experience compared to established pharmaceutical giants.
Opportunities
- Growing market demand for effective treatments for B-cell malignancies and autoimmune diseases.
- Potential for expanded indications and combination therapies.
- Strategic partnerships and collaborations to accelerate development and market access.
- Advancements in understanding disease mechanisms that could validate its therapeutic approach.
Threats
- Competition from established pharmaceutical companies with broader portfolios and resources.
- Regulatory hurdles and potential rejections or delays in approvals.
- Clinical trial failures or adverse events impacting drug development.
- Pricing pressures and reimbursement challenges in the healthcare market.
Competitors and Market Share
Key Competitors
- Genentech/Roche (RHHBY)
- AbbVie (ABBV)
- Janssen (JNJ)
- Gilead Sciences (GILD)
Competitive Landscape
TG Therapeutics Inc. faces intense competition from large, established pharmaceutical companies with significant resources and existing market share in oncology and immunology. Its advantages lie in its focused pipeline and potentially novel mechanisms of action for its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by scientific progress, successful fundraising, and advancement of its clinical pipeline through various phases of development.
Future Projections: Future growth is contingent on successful regulatory approvals of its lead drug candidates, Ublituximab and Umbralisib, and subsequent commercialization. Analyst projections will focus on potential peak sales and market penetration.
Recent Initiatives: Recent initiatives include advancing late-stage clinical trials, preparing for regulatory submissions, and potentially engaging in strategic partnerships or collaborations.
Summary
TG Therapeutics Inc. is a biopharmaceutical company with promising drug candidates in oncology and immunology. Its strengths lie in its innovative pipeline and experienced leadership. However, it faces significant competition and the inherent risks of drug development and regulatory approval. Successful execution of clinical trials and regulatory strategies will be crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- TG Therapeutics Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Analysis Reports
- Financial News Outlets
Disclaimers:
This information is for analytical purposes only and does not constitute investment advice. Financial data and market share figures are estimates and subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TG Therapeutics Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 1995-12-14 | Chairman, CEO & President Mr. Michael S. Weiss Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 374 | Website https://www.tgtherapeutics.com |
Full time employees 374 | Website https://www.tgtherapeutics.com | ||
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.